MyoKardia, Inc. (NASDAQ:MYOK) major shareholder Rock Ventures Ii L.P. Third sold 221,250 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $41.30, for a total transaction of $9,137,625.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
MyoKardia, Inc. (NASDAQ MYOK) traded down 1.79% during trading on Tuesday, reaching $43.90. 331,736 shares of the company were exchanged. MyoKardia, Inc. has a 52-week low of $10.55 and a 52-week high of $45.85. The firm’s market cap is $1.38 billion. The firm has a 50-day moving average of $44.70 and a 200-day moving average of $17.16.
MyoKardia (NASDAQ:MYOK) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.04). MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $6.73 million. During the same period in the previous year, the company posted ($0.37) EPS. The firm’s revenue for the quarter was up 60.0% on a year-over-year basis. On average, equities analysts forecast that MyoKardia, Inc. will post ($1.64) EPS for the current year.
WARNING: “Rock Ventures Ii L.P. Third Sells 221,250 Shares of MyoKardia, Inc. (MYOK) Stock” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thestockobserver.com/2017/09/12/rock-ventures-ii-l-p-third-sells-221250-shares-of-myokardia-inc-myok-stock.html.
A number of equities analysts recently commented on the stock. ValuEngine raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. BMO Capital Markets reaffirmed a “buy” rating and issued a $45.00 price objective (up previously from $32.00) on shares of MyoKardia in a research note on Tuesday, August 8th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $48.00 price objective (up previously from $31.00) on shares of MyoKardia in a research note on Monday, August 7th. Cowen and Company raised their price objective on shares of MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a research note on Monday, August 7th. Finally, TheStreet lowered shares of MyoKardia from a “c-” rating to a “d+” rating in a research note on Friday, May 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $41.60.
Large investors have recently modified their holdings of the business. Teachers Advisors LLC boosted its holdings in shares of MyoKardia by 42.1% in the fourth quarter. Teachers Advisors LLC now owns 28,145 shares of the biotechnology company’s stock valued at $364,000 after buying an additional 8,342 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of MyoKardia by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 56,605 shares of the biotechnology company’s stock valued at $744,000 after buying an additional 8,469 shares during the period. Trexquant Investment LP boosted its holdings in shares of MyoKardia by 134.5% in the first quarter. Trexquant Investment LP now owns 37,987 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 21,787 shares during the period. Fernwood Investment Management LLC boosted its holdings in shares of MyoKardia by 0.8% in the first quarter. Fernwood Investment Management LLC now owns 43,323 shares of the biotechnology company’s stock valued at $570,000 after buying an additional 327 shares during the period. Finally, Aberdeen Asset Management PLC UK boosted its holdings in shares of MyoKardia by 85.2% in the first quarter. Aberdeen Asset Management PLC UK now owns 20,549 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 9,451 shares during the period. 42.94% of the stock is owned by hedge funds and other institutional investors.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.